Navigating Your ED Treatment Options: A Physiological and Practical Breakdown

Erectile dysfunction is among the most prevalent yet least openly discussed conditions in American men's health. Estimates from the Cleveland Clinic suggest that ED affects roughly 30 million men in the United States, with prevalence increasing significantly after age 40. Despite its commonality, many men delay seeking treatment for months or even years—often due to embarrassment, misinformation, or simply not knowing where to begin.

At MedIQ Shop, we believe that informed patients make better health decisions. This guide is designed to demystify the pharmacological options available for ED, explain the science behind how they work, and help you build a productive conversation with your physician or licensed prescriber.

What Actually Causes Erectile Dysfunction?

Before evaluating treatment options, it helps to understand the underlying physiology. Erections are primarily a vascular event. Sexual arousal triggers the release of nitric oxide in penile tissue, which in turn activates an enzyme called guanylate cyclase. This enzyme produces cyclic guanosine monophosphate (cGMP), a molecule that relaxes smooth muscle in the corpus cavernosum—the spongy tissue running the length of the penis—allowing blood to flow in and create an erection.

The problem in most ED cases is that an enzyme called phosphodiesterase type 5 (PDE5) breaks down cGMP too quickly, preventing sufficient blood flow. This is where the primary class of ED medications enters the picture.

PDE5 Inhibitors: The First-Line Standard of Care

Phosphodiesterase type 5 inhibitors—commonly referred to as PDE5 inhibitors—are the most widely prescribed and clinically validated medications for erectile dysfunction. They work by blocking the PDE5 enzyme, thereby preserving cGMP levels and sustaining the vascular response needed for an erection. Critically, these medications do not produce erections independently; sexual stimulation is still required.

The four FDA-approved PDE5 inhibitors currently available in the United States are sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). Each shares the same basic mechanism but differs meaningfully in onset time, duration of action, dosing flexibility, and side effect profile.

Sildenafil (Viagra and Generic Equivalents)

Sildenafil was the first PDE5 inhibitor approved by the FDA, receiving clearance in 1998. It typically takes effect within 30 to 60 minutes and remains active for approximately four to six hours. It is generally taken on an as-needed basis and should be consumed on an empty or light-meal stomach, as high-fat foods can delay absorption by up to an hour.

Generic sildenafil became widely available in the United States after 2017, significantly reducing cost. Standard doses range from 25 mg to 100 mg, with most men starting at 50 mg.

Tadalafil (Cialis and Generic Equivalents)

Tadalafil distinguishes itself through its extended duration of action—up to 36 hours—earning it the colloquial nickname "the weekend pill." This longer window allows for more spontaneity compared to sildenafil, as men do not need to time the dose as precisely relative to sexual activity.

Tadalafil is also uniquely available in a low-dose daily formulation (2.5 mg or 5 mg), which maintains steady-state plasma levels and eliminates the need for on-demand dosing altogether. This option is particularly appealing for men who are sexually active multiple times per week or who prefer not to associate pill-taking with planned intimacy.

Generic tadalafil is now widely accessible and considerably more affordable than the branded version. It is available through licensed online pharmacies, including MedIQ Shop, following a proper medical consultation.

Vardenafil (Levitra) and Avanafil (Stendra)

Vardenafil has a similar onset and duration profile to sildenafil but may be slightly more potent at equivalent doses. It is sometimes preferred by men who experience more pronounced visual side effects with sildenafil, as it has a marginally different selectivity profile for PDE5 versus PDE6 (an enzyme in the retina).

Avanafil is the newest of the four, approved in 2012. Its primary advantage is a rapid onset—some studies suggest effectiveness in as little as 15 minutes—and a reportedly cleaner side effect profile due to its high selectivity for PDE5 over other PDE subtypes.

Comparing Efficacy and Side Effects

Clinical trials across all four medications consistently show response rates between 60% and 85% in men with ED of varying etiologies, including psychogenic, vasculogenic, and diabetic causes. No single agent has demonstrated conclusive superiority in head-to-head trials, meaning individual response and tolerability often determine the best choice for a given patient.

Common side effects shared across the class include headache, facial flushing, nasal congestion, and dyspepsia. Tadalafil is more frequently associated with back pain and myalgia due to its inhibition of PDE11, which is found in skeletal muscle. Visual disturbances—described as a bluish tint or increased light sensitivity—occur more often with sildenafil.

All PDE5 inhibitors carry a contraindication with nitrate medications (such as nitroglycerin), as the combination can cause a dangerous, potentially life-threatening drop in blood pressure. This is a critical point to disclose to any prescriber.

Non-PDE5 Options: When First-Line Therapy Falls Short

For men who do not respond adequately to oral PDE5 inhibitors—or who have contraindications—other approaches exist. Alprostadil, a prostaglandin E1 analogue, is available as a urethral suppository (MUSE) or as an injectable formulation (Caverject). These options are highly effective but less commonly used due to the administration method involved.

In cases where hormonal imbalance contributes to ED, testosterone replacement therapy may be indicated, though it is typically used as an adjunct rather than a standalone treatment. Vacuum erection devices and penile implants represent additional options for refractory cases.

Cost Considerations and Accessing Medications Responsibly

The cost of branded ED medications in the United States has historically been prohibitive for many patients. However, the availability of FDA-approved generics has fundamentally changed the accessibility equation. Generic sildenafil and tadalafil can be obtained for a fraction of the original brand cost through licensed pharmacies.

MedIQ Shop facilitates access to these medications through a discreet, medically supervised process. Patients complete a health intake, connect with a licensed prescriber, and—if appropriate—receive their medication delivered in unmarked packaging directly to their home. This model removes the logistical and social barriers that prevent many men from seeking care.

Building a Productive Conversation with Your Healthcare Provider

If you are considering ED treatment, arriving at your appointment prepared can make a significant difference. Be ready to disclose all current medications (particularly nitrates, alpha-blockers, and antihypertensives), any cardiovascular history, and whether you have been evaluated for underlying causes such as diabetes or hypogonadism.

Ask specifically about daily versus on-demand dosing options, what to do if the first medication does not work, and whether any lifestyle modifications—such as weight loss, reduced alcohol consumption, or increased aerobic exercise—might improve your response to treatment.

ED is a medical condition, not a character flaw. Effective, evidence-based treatments exist, and the first step is simply choosing to pursue them.